EscharEx- Phase III VALUE trial advancing; interim assessment and enrollment completion expected by the end of the first quarter of 2027 First quarter revenue of $1.5 million; full-year 2026 revenue ...

Important progress across four clinical-stage programs demonstrating depth and breadth of obesity pipeline Initiated five ...

Sapience Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery and development of peptide ...

The Blue Earth County Board held a work session Tuesday to discuss updates surrounding the dam removal project. The project, led by County Engineer Ryan Thilges and Barr Project Manager Joe Hjerpe, is ...

Important progress across four clinical-stage programs demonstrating depth and breadth of obesity pipeline Initiated five late-stage global clinical trials in obesity, including the ribupatide injecti ...

The biotechnology company has completed enrollment in its placebo-controlled study of intranasal foralumab, with late-stage data expected in 2026.

HV-106 study enrolment completed; doses selected for the global Phase 3 pivotal program of GH001 in TRDGH001-HV-109 US IND-opening study enrolment completedCash, cash equivalents and marketable ...

Live updates from SpaceX’s weather-scrubbed NASA CRS-34 mission Wednesday, May 13, from Cape Canaveral Space Force Station in ...

The roughly $9.5 million demolition project began in November. The site is scheduled to be fully cleared by mid- to late-2027 ...

"We expect to begin recording product revenue from DARE to PLAY in the third quarter of 2026" (Chief Accounting Officer Haring-Layton), while adding, "Flora Sync LF5 consumer health product revenue is ...

According to the Election Commission, this phase covers states and Union Territories such as Uttarakhand, Andhra Pradesh, ...

Data reinforce WVE-006’s potential to address both lung and liver manifestations of AATD with a durable, convenient, and safe therapy capable of ...